Methods for the treatment of cancer using double negative T cells (DNTs) and a PD-1 or PD-L1 inhibitor are described. Tumors treated with DNTs and a PD-1 inhibitor exhibited increased DNT cell infiltration and increased cytotoxicity towards non-small cell lung cancer (NSCLC) cells. Also described are compositions and kits comprising DNTs and a PD-1 or PD-L1 inhibitor and their use for the treatment of cancer.
